Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

113 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, Kim DDH, Saussele S, Annunziata M, Chaudhri N, Chee L, García-Gutiérrez V, Kapoor S, Allepuz A, Quenet S, Bédoucha V, Mauro MJ. Hochhaus A, et al. Among authors: allepuz a. Leukemia. 2023 Mar;37(3):617-626. doi: 10.1038/s41375-023-01829-9. Epub 2023 Jan 30. Leukemia. 2023. PMID: 36717654 Free PMC article. Clinical Trial.
Phase 2 study of nilotinib in pediatric patients with Philadelphia chromosome-positive chronic myeloid leukemia.
Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Aimone P, Allepuz A, Quenet S, Hourcade-Potelleret F, Hertle S, Sosothikul D. Hijiya N, et al. Among authors: allepuz a. Blood. 2019 Dec 5;134(23):2036-2045. doi: 10.1182/blood.2019000069. Blood. 2019. PMID: 31511239 Free PMC article. Clinical Trial.
A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
Réa D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, Hughes TP, Chaudhri N, Sasaki K, Chee L, García-Gutiérrez V, Cortes JE, Aimone P, Allepuz A, Quenet S, Bédoucha V, Hochhaus A. Réa D, et al. Among authors: allepuz a. Blood. 2021 Nov 25;138(21):2031-2041. doi: 10.1182/blood.2020009984. Blood. 2021. PMID: 34407542 Free PMC article. Clinical Trial.
[No title available]
[No authors listed] [No authors listed] PMID: 36163925
Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
Yuda J, Doki N, Matsuoka H, Yokota T, Tomita A, Takahashi N, Matsumura I, Kubo K, Goto T, Kirito K, Maki A, Aoki M, Allepuz A, Minami Y. Yuda J, et al. Among authors: allepuz a. Cancer Med. 2023 Feb;12(3):2990-2998. doi: 10.1002/cam4.5212. Epub 2022 Sep 27. Cancer Med. 2023. PMID: 36168187 Free PMC article. Clinical Trial.
Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
Réa D, Boquimpani C, Mauro MJ, Minami Y, Allepuz A, Maheshwari VK, D'Alessio D, Wu Y, Lawrance R, Narbutas S, Sharf G, Hochhaus A. Réa D, et al. Among authors: allepuz a. Leukemia. 2023 May;37(5):1060-1067. doi: 10.1038/s41375-023-01888-y. Epub 2023 Apr 14. Leukemia. 2023. PMID: 37069326 Free PMC article. Clinical Trial.
A phase 2 study of nilotinib in pediatric patients with CML: long-term update on growth retardation and safety.
Hijiya N, Maschan A, Rizzari C, Shimada H, Dufour C, Goto H, Kang HJ, Guinipero T, Karakas Z, Bautista F, Ducassou S, Yoo KH, Zwaan CM, Millot F, Patterson B, Samis J, Aimone P, Allepuz A, Titorenko K, Sosothikul D. Hijiya N, et al. Among authors: allepuz a. Blood Adv. 2021 Jul 27;5(14):2925-2934. doi: 10.1182/bloodadvances.2020003759. Blood Adv. 2021. PMID: 34309636 Free PMC article. Clinical Trial.
Corrigendum: Examination of critical factors influencing ruminant disease dynamics in the Black Sea Basin.
Arede M, Beltrán-Alcrudo D, Aliyev J, Chaligava T, Keskin I, Markosyan T, Morozov D, Oste S, Pavlenko A, Ponea M, Starciuc N, Zdravkova A, Raizman E, Casal J, Allepuz A. Arede M, et al. Among authors: allepuz a. Front Vet Sci. 2024 Feb 28;11:1376956. doi: 10.3389/fvets.2024.1376956. eCollection 2024. Front Vet Sci. 2024. PMID: 38482166 Free PMC article.
113 results